Tripokin is a fully-human immunostimulatory product consisting of tumor necrosis factor (TNF) and interleukin-2 (IL2) fused into one molecular entity.
TNF induces a rapid hemorrhagic tumor necrosis, while IL2 stimulates cancer-specific immune effector cells, when delivered to the site of disease. The fusion to the L19 antibody, which is specific to the EDB domain of fibronectin, generates a tumor targeted product that selectively localizes at the site of disease, while sparing healthy organs.
Tripokin capitalizes of the synergistic mechanism of action of TNF and IL2 . The products has shown a strong anti-tumor activity as single agent in various preclinical models of cancer. Tripokin exhibits excellent tumor-homing properties and the most potent activity ever reported for IL2-based therapeutics. These best-in-class therapeutic properties can be further potentiated by combination therapies with immune check-point inhibitors.
Tripokin is the next biotherapeutic candidate that Philogen aims to bring to the clinic.
![Tripokin-Philogen](https://www.philogen.com/philogen/wp-content/uploads/2021/06/Tripokin-Philogen.jpg)
References
De Luca et al.(2019) Frontiers in Oncology, 9, 1228
De Luca et al. (2018) Cancer Immunology Immunotherapy, 67, 1381-91
De Luca et al. (2017) Mol Cancer Ther, 16, 2442-51
Schwager et al. (2013) J Invest Dermatol, 133, 751-8